Skip to main content

Table 1 Study characteristics

From: Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

 

Total number of included studies

Hong [29]

Kaneda [33]

Kernan (IRIS) [2]

Lee [30]

Nishio [34]

Nissen (PERISCOPE) [9]

Suryadevara [31]

Takagi (POPPS) [32]

Tanaka (J-SPIRIT) [8]

Dormandy (PROactive) [10, 35, 36]

Population

 Type 2 diabetes + CVD

7

X

  

X

X

X

X

X

 

X

 Type 2 diabetes + no diabetes + CVD

1

 

X

        

 Abnormal glucose metabolism without diabetes + CVD

2

  

X

     

X

 

 Patients undergoing PCI

5

X

X

 

X

X

  

X

  

Type of pioglitazone treatment

 Pioglitazone 15 mg/d

2

X

  

X

      

 Pioglitazone 30 mg/d

3

    

X

 

X

X

  

 Pioglitazone 45 mg/d

1

  

X

       

 Pioglitazone 15–30 mg/d

2

 

X

      

X

 

 Pioglitazone 15–45 mg/d

2

     

X

   

X

Treatment in control group

 None

4

 

X

  

X

  

X

X

 

 Placebo

5

X

 

X

X

  

X

  

X

 Glimepiride

1

     

X

    

Extracted outcome of interest

 Major adverse c cardiac/Cardiovascular disease

8

X

X

X

X

X

X

 

X

 

X

 Myocardial infarction

8

X

X

X

X

X

X

 

X

 

X

 Stroke

4

  

X

  

X

  

X

X

 All-cause mortality

8

 

X

X

X

 

X

X

X

X

X

 Heart failure

6

X

X

X

  

X

 

X

X

X

  1. CVD cardiovascular disease, PCI percutaneous coronary intervention